



SIGNIFICANCE OF IMMUNOCYTOCHEMISTRY ON SPUTUM SAMPLES FOR THE DIFFERENTIAL DIAGNOSIS OF LUNG ADENOCARCINOMA

Kokare Disha Laxman¹, Khamkar S.P²

¹Student (B pharm), Department of pharmaceutical chemistry pharmacy Late Narayandas Bhavandas Chhabada Institute of pharmacy, Raigaon, Satara, Shivaji university, Kolhapur, Maharashtra, India

²Asst. Prof., Department of pharmaceutical chemistry pharmacy Late Narayandas Bhavandas Chhabada Institute of pharmacy, Raigaon, Satara, Shivaji university, Kolhapur, Maharashtra, India

Telephone no: +919324523152, +919763416349

Gmail: disha.kokare99@gmail.com, khamkarsurekha9@gmail.com

ABSTRACT

Despite the fact that sputum cytology is widely acknowledged as a straightforward and noninvasive diagnostic technique for lung cancer, clinical trials are still ongoing. The value of sputum in determining prognosis has determined. Indicators for targeted therapy, prognosis prediction will be quite useful.

Keywords: *Immunocytochemistry, carcinoma, treatment, sputum.*

1. INTRODUCTION

Non-small-cell lung carcinoma (NSCLC) is a very diverse disease that accounts for approximately 75–85 percent of lung malignancies. In the last two decades, there has been no significant improvement in survival rates. The most important prognostic factor for lung cancer is tumour stage. It serves as the foundation for selecting a treatment option. [2] The recurrence rate is extremely high, even in early-stage disease. Furthermore, patients with the same stage of cancer had drastically different prognoses. As a result, predictive indicators play a critical role in adjuvant therapy selection, lowering the risk of recurrence and increasing the possibility of survival. Multiple indicators may be needed due to the variety and complexity of lung cancer.

As a result, predictive markers are crucial in selecting which adjuvant therapy to utilise in order to lower the risk of recurrence and increase the survival rate. Various research have discovered oncogenes and tumour suppressor genes as possible oncogenes and tumour suppressor genes. Patients with NSCLC have prognostic indications that can help predict survival. Sputum samples are rarely used in lung cancer diagnosis and subclassification. It was used for it. We recently published a paper on sputum homogenization methods.

Wherein the sputum's whole-cell content can be efficiently employed for morphological examination.

Sputum cytology, with technology, can play a significant role in lung cancer diagnosis. Immunocytochemistry has also been used in sputum samples and is extensively established. [6] In the event that a panel validation of a set of reliable markers for the differential diagnosis of lung cancer patients if there is adenocarcinoma in the sputum sample itself. cancer patients in picking specific therapy, without sophisticated

Bronchoscopy and biopsy are examples. [7] TTF-1 is responsible for a variety of functions in the lungs. Surfactant proteins A, B, C, and Clara cell secretory proteins transcriptional activation proteins. The survival of pulmonary neoplasms has been discovered to be varied. (8)

The immunorexpression of these markers was investigated in tissue samples in the majority of prior investigations. However, liquid-based cytology (LBC) preparations, particularly bronchial washings, are becoming more popular these days and brushings, and have been demonstrated to outperform traditional methods. [12] Since the introduction of LBC, diagnosis accuracy has improved. lowered the time it took to screen and assisted in the removal of distracting backdrop blood and materials [13] Furthermore, LBC cell fixation may be superior to other methods.

For immunocytochemistry, 95 percent ethanol fixation was used. SurePath is a thin-layer LBC technique that relies on a sedimentation process with CytoRich. In non-gynecologic cytology, a red solution is used. [14]

Homogenization of sputum with The CytoRich Red solution provides the sputum's entire cell content. This sample can be utilised for morphological analysis.(15)

Carcinoma:

Carcinoma is a cancerous tumour that arises from epithelial recells.[1]Carcinoma is a type of cancer that starts in the tissue that lines the inside or outside of the body.cells that originate in the endodermal, mesodermal[2] layers of the body Carcinomas develop when a cell's DNA is broken or mutated, and the cell dies. It starts to grow out of control and becomes cancerous. It comes from Greek: v, romanized as karkinoma, means'sore, ulcer, cancer'[3].Cancer is one of a kind.

Skin cancer, also known as basal cell carcinoma, is a kind of cancer that affects the skin. A form of cancer that affects the skin is squamous cell carcinoma. Adenocarcinoma is a type of cancer that affects the lungs. Basal cell carcinoma is a type of skin cancer.The most frequent type of skin cancer is basal cell carcinoma.Cancerous cells form in the skin's basal cell layer, or the lowest layer.

Basal cell tumours are slow-growing malignancies that rarely spread.metastasis, causing cancer to spread to surrounding lymph nodes or other regions of the body.Squamous cell carcinoma is a type of cancer that affects the skin.Squamous cell carcinoma is a kind of skin cancer that develops in the squamous cells.Squamous cells are a type of squamous cell.

These are flat, fish-scale like cells that border the outside of the skin and the inside of the body.Hollow organs, such as the cervix and vagina, are examples.Squamous cell carcinoma is a type of skin cancer that begins on the surface of the skin.Changes are noticed pretty fast. As a result, they will be able to begin treatment sooner.

A kind of skin cancer known as basal cell carcinoma.Basal cell carcinoma is the most common type of skin cancer.The basal cell layer, or the lowest layer of the skin, is where cancerous cells develop.The epidermis is the skin's outer layer. Basal cell tumours are benign tumours that grow slowly and rarely spread.metastasis is when cancer spreads to nearby lymph nodes or other parts of the body.A form of cancer that affects the skin is squamous cell carcinoma.Skin cancer that originates in the squamous cells is known as squamous cell carcinoma.A form of squamous cell is a squamous cell. These are flat, fish-scale-like cells that line the inside and outside of the body.The cervix, for example, is a hollow organ.

Treatment:


The treatment you receive will be determined on the type of cancer you have.The goal of cancer treatment is to find a way to cure your illness.enabling you to live a regular life expectancy This may or may not be the case.It's conceivable, depending on your circumstances. If there isn't a cure,Your treatments may be used to decrease or slow the progression of your cancer.help slow the progression of your cancer so you can live symptom free for as long as possible as much as possible.

Cancer Treatment Biomarker Testing:

Chemotherapy is number one. 2. Thermogenesis Immunotherapy is the third option. Photodynamic Therapy (PDT)

Radiation therapy is number five. Transplantation of stem cells is number six. 7. Surgical procedures Targeted Therapy (#8) Lung Cancer is a type of cancer that affects the Lung cancer is a cancer In your chest, you have two sponge-like organs called lungs. Your right lung is in good shape. There are three lobes in this structure. There are two lobes in your left lung. The left lung is dilated. Because the heart occupies more space on that side of the body, it is smaller Body. The trachea is divided into bronchi, which enter and split the lungs.into bronchioles of a smaller size These split into smaller branches known as bronchioles. Tiny air sacs called bronchioles are located at the end of the bronchioles When you inhale, the alveoli absorb oxygen into your blood and exhale, they eliminate carbon dioxide from your blood. The major functions of your lungs are to take in oxygen and expel carbon dioxide functions.

The diaphragm, a narrow, domeshaped muscle that separates the chest from the abdomen, contains the lungs.



The diaphragm swings up and down while you breathe, propelling air into and out of your lungs.

Lung cancer is divided into two types.

Adenocarcinoma is a type of cancer that affects the lungs.

Lung adenocarcinoma (LUAD) is a common non-small-cell lung cancer. NSCLC (non-small cell lung cancer) [1].

Adenocarcinoma with a localised adenocarcinoma (stage I) [3]. However, the majority of people with LUAD is diagnosed after the cancer has spread to other parts of the body.

This results in a dismally low survival rate [4, 5]

In numerous malignancies, the tumour microenvironment (TME) and the structure of the local extracellular matrix (ECM) have been discovered to be important roles in tumour growth and metastasis [6–8]. The interplay

Multiple factors are influenced by the interaction between tumour cells and immune cells.

[9] is thought to be a potential therapeutic method. TAMs (tumor-associated macrophages) are also a common cell type. The population in the TME may be able to control the expression of certain genes.

PD-L1 and phagocytosis are immunosuppressive molecules.

inhibitors, increasing tumour growth and resistance to chemotherapy. [10] therapy

Many collagen types have undergone change [11], and it's possible that it's involved in a variety of disea

in breast cancer [13]. proliferation and invasiveness of bladder cancer [14]. Moreover, P3H4 is inses. Microenvironment of the tumour [12]

P3H2 and P3H3 are two members of the P3H gene family that have been identified as novel epigenetic silencing targets based on sequence similarity. P3H2 and P3H3 are involved in a complex that is required for the cross-linking of collagen fibrils, and collagen cross-linking has been shown to promote tumour cell proliferation and metastasis [16, 17].

P3H2 and P3H3, two members of the P3H gene family, have been identified as novel epigenetic silencing targets in breast cancer [13]. Knocking down P3H4 in bladder cancer would result in a halt in the progression of the disease. reduced expression levels of EMT-related proteins, and cell cycle implying that silencing P3H4 could effectively prevent

bladder cancer's uncontrolled proliferation and invasiveness [14]. Furthermore, there is a link between elevated P3H4 expression and the In patients with a high pathological stage and a poor prognosis. [15] Bladder cancer

P3H4 is also deduced from the sequence. similarity to be in a complex, which is required for collagen cross-linking We did research in this article. a thorough examination of P3H4 in tumour tissues at both the microscopic and microscopic levels

Sputum

When a person's lungs are infected or injured, sputum is generated. Sputum is the thick mucus – also known as phlegm – coughed up from the lungs, not saliva. Mucus is produced by the body to protect the thin, sensitive tissues of the lungs. Keeping the respiratory system wet prevents microscopic particles of foreign substances from entering the lungs. Can be trapped and driven out if they represent a threat. An infection in the lungs, for example, can cause an infection in the lungs. An excessive amount of mucus is produced. The body makes an effort to get rid of it. extra sputum by coughing it up. In a sputum culture test, a gramme stain is utilised to identify the bacteria that are causing the infection. Specialized tests are required if the gramme stain fails to identify the bacteria that is causing the infection. Tests can also be carried out.. An AFB smear and culture are two of them. tuberculosis and non-tuberculous mycobacteria infections, a tuberculosis and non-tuberculous mycobacteria infections, a tuberculosis and non Legionella culture or fungal culture A sputum sample is normally taken first thing in the morning. morning. Up to three additional times, depending on the infection. The following days may be used to collect samples.

People who are being sent for a sputum test may be requested to brush their teeth, rinse their mouth with water, and refrain from eating for 1-2 hours before the test. A person is required to take a sample from their lungs in order to obtain a sample. Coughing deeply is typically requested. If no one can come up with any, They may be asked to inhale sterile saline or glycerine if they have sputum.

To loosen phlegm in the lungs, use this solution. Inhaling steam has the potential to improve your health. At occasion, it may also be utilised.

A doctor may also request someone to perform a sputum culture test in addition to a sputum culture test. Check your blood for any additional symptoms of illness with a full blood count.

Immunocytochemistry in Sputum

Predicts Lung Cancer Prognosis Immunocytochemistry in Sputum Samples Predicts Lung Cancer Prognosis Despite the fact that sputum cytology is widely considered as a simple and effective test, The clinical trial of a noninvasive lung cancer diagnostic method.

The value of sputum in determining prognosis has yet to be determined. explored. Some sputum markers for prognosis have been validated. For targeted therapy, prediction will be quite useful.

2. CONCLUSION

This is the first time immunocytochemistry has been used to examine exfoliated cells in sputum samples, implying that more research is needed. Immunocytochemical markers can be found in sputum samples. as a reliable and cost-effective prognostic and survival predictor Galectin3 overexpression, mutant p53 accumulation, and lower levels of the p16 and EGFR proteins have all been related to an increased risk of cancer. The prognosis for lung cancer is poor.

REFERENCES

1. Travis WD, Brambilla E, Burke AP, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon: IARC Press; 2015.
2. Tockman MS. Advances in sputum analysis for screening and early detection of lung cancer. *Cancer Control* 2000;7:19–24. PubMed Google Scholar
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with insensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306-11. [Crossref] [PubMed]
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39. [Crossref] [PubMed]
5. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol* 2012;30:863-70. [Crossref] [PubMed]
6. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. *Genes Dev.* 1996;10:1945–52. [PubMed] [Google Scholar]
7. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. *Lung Cancer.* 2001;33(Suppl 1):S17–24. [PubMed] [Google Scholar]
8. Gazzari S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. *Oncogene.* 1998;16:497–504. [PubMed] [Google Scholar]
9. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. *Cancer Res.* 1996;56:3415–20. [PubMed] [Google Scholar]
10. Huncharek M, Kupelnick B, Geschwind JF, Caubet JF. Prognostic significance of p53 mutations in non-small cell lung cancer: A meta-analysis of 829 cases from eight published studies. *Cancer Lett.* 2000;153:219–26. [PubMed] [Google Scholar]
11. Cheng YL, Lee SC, Harn HJ, Chen CJ, Chang YC, Chen JC, et al. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer. *Eur J Cardiothorac Surg.* 2003;23:221–8. [PubMed] [Google Scholar]
12. Gerads J, Fong KM, Zimmerman PV, Maynard R, Minna JD. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. *Clin Cancer Res.* 1999;5:791–800. [PubMed] [Google Scholar]
13. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon HE, Komoto Y, Oue T, et al. Inversely correlated expression of p16 and rb protein in non-small cell lung cancers: An immunohistochemical study. *Int J Cancer.* 1996;65:442–5. [PubMed] [Google Scholar]